{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=31", "query": { "condition": "Cancer,", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 50439, "total_pages": 5044, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T03:14:54.178Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02658396", "title": "GO-203-2C + Bortezomib For Relapsed Or Refractory MM", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "GO-203-2C", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": "2022-01", "has_results": false, "last_update_posted_date": "2017-07-05", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02658396" }, { "nct_id": "NCT00228696", "title": "National Wilm's Tumor Study Late Effects", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Wilm's Tumor" ], "interventions": [ { "name": "none, screening only", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2005-09", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2013-11-26", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00228696" }, { "nct_id": "NCT00591396", "title": "A Phase I Trial of ZIO-101 in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ZIO-101 (Darinaparsin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2005-07", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2012-07-19", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00591396" }, { "nct_id": "NCT03505762", "title": "Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-07-19", "completion_date": "2029-06", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03505762" }, { "nct_id": "NCT06014762", "title": "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High-grade B-cell Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Transformed Follicular Lymphoma (tFL)", "Follicular Lymphoma Grade 3B", "DLBCL", "DLBCL - Diffuse Large B Cell Lymphoma", "DLBCL Arising From Follicular Lymphoma", "DLBCL, Diffused Large B Cell Lymphoma", "DLBCL NOS" ], "interventions": [ { "name": "P-CD19CD20-ALLO1", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Poseida Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-04-16", "completion_date": "2041-03", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 16, "location_summary": "Loma Linda, California • Los Angeles, California • Orlando, Florida + 13 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06014762" }, { "nct_id": "NCT01568346", "title": "Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "MRI", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2012-02", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2016-08-02", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01568346" }, { "nct_id": "NCT05022446", "title": "The Impact of COVID-19 on Pulmonary Procedures", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19 Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 250, "start_date": "2020-11-11", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05022446" }, { "nct_id": "NCT01542203", "title": "Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2012-06-25", "completion_date": "2017-06-05", "has_results": false, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01542203" }, { "nct_id": "NCT05394103", "title": "Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "Mocaciclib (Q901)", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qurient Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-08-30", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-11-09", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05394103" }, { "nct_id": "NCT03377361", "title": "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Colorectal Tumors", "Colorectal Carcinoma", "Colorectal Neoplasm" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2018-01-31", "completion_date": "2024-11-04", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-11-15T03:14:54.178Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03377361" } ] }